DEF: Replimune Group Sets 2025 Annual Meeting, Seeks Shareholder Approval for Board and Expanded Equity Plan

Replimune Group, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 3, 2025, seeking approval for director elections, auditor ratification, executive compensation, and an amendment to its incentive compensation plan.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Wednesday, September 3, 2025, at 11:30 a.m. Eastern Time.
• The record date for stockholders entitled to vote is July 16, 2025, with proxy materials being sent on or about July 25, 2025.
• Shareholders will vote on the election of five Class I directors: Philip Astley-Sparke, Kapil Dhingra, Michael Goller, Christy Oliger, and Joseph Slattery, each for a three-year term until the 2028 Annual Meeting.
• A proposal seeks to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
• A non-binding advisory vote will be held on the compensation of the company's named executive officers for the fiscal year ended March 31, 2025.
• An amendment to the 2018 Omnibus Incentive Compensation Plan is proposed to revise the 'Evergreen Provision' from 4% to 5% of outstanding shares added annually to the share pool.
• As of June 30, 2025, the company had 77,807,174 shares of common stock outstanding.
• Net Loss for fiscal year ended March 31, 2025, was $247.3 million, compared to $215.8 million in FY2024 and $174.3 million in FY2023.
• The year-end value of $100 invested on March 31, 2022, was $57.42 by March 31, 2025, down from $104.00 in FY2023 and $48.12 in FY2024.

Sentiment

Score: 4

Explanation: The filing is a standard proxy statement focused on governance and compensation, which are generally neutral. However, the disclosed worsening net loss and significant decline in TSR indicate negative financial performance. The proposed increase in the equity incentive plan's evergreen provision could be viewed negatively due to potential dilution, despite its stated purpose of talent retention.

Positives

• The company maintains a robust corporate governance structure with a classified board, independent directors, and dedicated committees for Audit, Compensation, Nominating and Corporate Governance, and Research & Development.
• The Board of Directors unanimously recommends voting FOR all proposals, indicating internal alignment on key governance and compensation matters.
• Executive compensation is designed to align with stockholder interests through a pay-for-performance philosophy, utilizing base salary, annual cash incentives, and long-term equity incentives.
• The company has an independent executive compensation consultant (Pearl Meyer) providing advice and recommendations on executive officer compensation arrangements.
• The company has adopted a Compensation Recoupment Policy (Clawback Policy) effective November 20, 2023, aligning with regulatory requirements and good governance practices.

Negatives

• Net Loss increased year-over-year, from $174.3 million in FY2023 to $215.8 million in FY2024, and further to $247.3 million in FY2025.
• The year-end value of $100 invested on March 31, 2022, declined significantly to $57.42 by March 31, 2025, indicating a substantial decrease in Total Shareholder Return (TSR) over the period.
• The proposed amendment to increase the 2018 Omnibus Incentive Compensation Plan's 'Evergreen Provision' from 4% to 5% could lead to increased share dilution for existing stockholders.

Risks

• The Board of Directors oversees cybersecurity and information technology risks, receiving reports from management on related exposures, initiatives, and readiness programs.
• The Board also oversees broader Environmental, Social and Governance (ESG) issues to ensure appropriate management of ESG risks and opportunities.

Future Outlook

The company's future success depends significantly on its ability to attract and retain capable and experienced directors, and the proposed amendment to the 2018 Omnibus Incentive Compensation Plan is intended to support this by providing sufficient equity awards for key personnel. The company also aims to continue its research and development efforts and progress its product pipeline, with performance-based restricted stock units tied to the potential U.S. Food and Drug Administration approval of RP1 by June 30, 2026.

Management Comments

• Sushil Patel, Chief Executive Officer, stated, 'On behalf of the Board of Directors of Replimune Group, Inc., I invite you to attend our 2025 Annual Meeting of Stockholders.'

Industry Context

As a pre-commercial biotechnology company, the company operates in an industry characterized by long development timelines for biologics, requiring a board with deep knowledge and a long-term strategic focus. The emphasis on attracting and retaining key talent through equity incentives is a common practice in the highly competitive biopharmaceutical sector.

Comparison to Industry Standards

• The company's classified board structure is noted as providing stability, continuity, and experience, which is beneficial in the long-term focused biotechnology industry, similar to other companies requiring sustained strategic development.
• The compensation philosophy, which links executive equity awards to stockholder value creation, aligns with best practices in the biotechnology industry to incentivize long-term growth.
• The company's use of an independent executive compensation consultant (Pearl Meyer) for evaluating executive compensation aligns with common corporate governance standards for publicly traded companies.
• The adoption of a Clawback Policy is consistent with recent regulatory requirements (Dodd-Frank Act and Nasdaq listing rules) and reflects a commitment to modern corporate governance benchmarks.

Management Changes

Corporate Governance

Related Party Transactions

• Michael Goller, a member of the Board, is a Partner at Baker Bros. Advisors LP (BBA Funds), which is a beneficial owner of more than 5% of the company's capital stock.
• On March 5, 2025, the company entered into an Affiliate Registration Rights Agreement with the BBA Funds, granting them certain resale registration rights for company common stock and other securities.
• In June 2024, the BBA Funds participated in the company's private placement, purchasing 5,668,937 common shares and pre-funded warrants for 5,669,578 shares, contributing to approximately $96.7 million in net proceeds for the company.
• In November 2024, the BBA Funds participated in the company's underwritten public offering, purchasing pre-funded warrants for 3,846,184 shares, contributing to approximately $156.0 million in net proceeds for the company.

Stakeholder Impact

• Shareholders: Will vote on key governance matters, including director elections, auditor ratification, executive compensation, and a proposed increase in the equity incentive plan, which could impact dilution.
• Employees: The proposed amendment to the 2018 Omnibus Incentive Compensation Plan aims to attract, motivate, and retain key employees through equity awards.
• Management: Executive officers' compensation is subject to a non-binding advisory vote by shareholders, and their performance is evaluated against corporate goals for bonus determination.
• Directors: Compensation for non-employee directors includes cash retainers and annual option grants, aligning their interests with long-term company performance.

Next Steps

• The 2025 Annual Meeting of Stockholders will be held on September 3, 2025, where stockholders will vote on the proposed matters.
• The final voting results of the Annual Meeting will be disclosed in a Current Report on Form 8-K filed with the SEC within four business days after the meeting.
• The company will hold its next non-binding advisory 'say on pay' vote at the 2026 Annual Meeting of Stockholders.
• Stockholders wishing to submit proposals for the 2026 Annual Meeting proxy materials must do so by March 27, 2026.
• Stockholders wishing to bring business or nominations before the 2026 Annual Meeting must provide notice between May 6, 2026, and June 5, 2026.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Board of Directors, Equity Incentive Plan, Shareholder Vote, Biotechnology, SEC Filing, Replimune Group